Recent Cancer Treatment Linked to Worse COVID-19 Outcomes
However, a history of cancer more than one year before COVID-19 diagnosis not tied to increased mortality or hospitalization
Chemotherapy
Post-RC Radiation Does Not Up Survival in Locally Advanced Bladder Cancer
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
Study: Alternative to BCG in High-Risk NMIBC Shows Excellent Efficacy
Investigators report a 24-month recurrence-free survival rate of 82% with the use of intravesical gemcitabine/docetaxel following complete transurethral resection of bladder tumor.
Post-TURBT Gemcitabine Use Increased After Trial Results Published
Investigators said the findings of their cross-sectional study “highlight the power as well as the limitations of prominent RCTs.”
Women Face Higher Risk for Severe AEs From Cancer Therapy
Large differences in risks for severe adverse events according to sex seen for cancer patients receiving immunotherapy
Kidney Function Not Worse After RC With Continent Diversion in Stage 3a CKD
In a study, approximately half of patients with and without stage 3a CKD maintained their renal function after orthotopic neobladder formation.
Radical Cystectomy vs Trimodal Tx for cT3 MIBC May Offer Better Survival
Increasing T stage has been associated with reduced long-term survival after trimodal therapy.
Bladder Cancer Drug Shows Antitumor Activity in Cisplatin-Ineligible Patients
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
High-Risk NMIBC Effectively Treated With a BCG Alternative
Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.
Neoadjuvant Abiraterone Prior to Surgery Beneficial in High-Risk Prostate Cancer
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...